(4Z)-4-ethylidene-2-methyl-1,3-oxazol-5(4H)-one

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4Z)-4-ethylidene-2-methyl-1,3-oxazol-5(4H)-one
• 英文别名: (4Z)-4-ethylidene-2-methyl-1,3-oxazol-5-one
• 化学式: C₆H₇NO₂
• 分子量: 125.13
• InChiKey: OLVJRXINPGVCMV-HYXAFXHYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Compounds for the treatment of metabolic disorders
  申请人：Hodge L. Kirvin

  公开号：US20070173544A1

  公开（公告）日：2007-07-26

  Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 0 to 4; q is 0 or 1; t is 0 or 1; R 2 is alkyl having from 1 to 3 carbon atoms; R 3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalendy bound to the remainder of the compound of formula (I) by a ring carbon; and R 1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R 1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).

  本发明揭示了用于治疗各种代谢性疾病的药物，例如胰岛素抵抗综合征、糖尿病、高脂血症、脂肪肝病、消瘦、肥胖症、动脉粥样硬化和动脉硬化。其中，公式（I）中，n为1或2；m为0至4；q为0或1；t为0或1；R2为具有1至3个碳原子的烷基；R3为氢、卤素、具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基；A为苯基，未取代或由1或2个选择自：卤素、具有1或2个碳原子的烷基、全氟甲基、具有1或2个碳原子的烷氧基和全氟甲氧基的基团取代；或具有3至6个环碳原子的环烷基，其中环烷基未取代或一个或两个环碳原子独立地被甲基或乙基单取代；或具有1或2个选择自N、S和O的环外杂环的5或6元杂环，且杂环与公式（I）的余下部分通过环碳原子共价结合；R1为氢或具有1或2个碳原子的烷基。或者，当R1为氢时，生物活性剂可以是公式（I）化合物的药学上可接受的盐。
• AZLACTONE COMPOUND AND METHOD FOR PREPARATION THEREOF
  申请人：TAKAHASHI Daisuke

  公开号：US20080188667A1

  公开（公告）日：2008-08-07

  Compounds represented by formula (II): wherein M is a hydrogen atom, sodium, potassium, or lithium; P is a hydrogen atom, an alkyl group, and the like; and the wavy line indicates a cis form, a trans form, or a mixture thereof for the double bond to which it is attached, may be prepared by hydrolyzing a compound represented by formula (I), or a salt thereof: wherein R 1 and R 2 are the same or different and each is an alkyl group, or R 1 and R 2 together with the adjacent nitrogen atom may form an aliphatic heterocycle, and P and the wavy line are as defined above, in the presence of alkali metal hydroxide.
• US7358368B2
  申请人：——

  公开号：US7358368B2

  公开（公告）日：2008-04-15